A pan-HDAC inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SB939

Item No. 10443

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-2E-propenamide
CAS Number
929016-96-6
Synonyms
  • Pracinostat
Molecular Formula
C20H30N4O2
Formula Weight
358.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 5 mg/mlEthanol:PBS(pH 7.2) (1:1): 0.5 mg/ml
λmax
249, 303 nm
SMILES
CCN(CC)CCN1C2=C(N=C1CCCC)C=C(/C=C/C(NO)=O)C=C2
InChi Code
InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
InChi Key
JHDKZFFAIZKUCU-ZRDIBKRKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $49

    Add

    5 mg

    $154

    Add

    10 mg

    $283

    Add

    25 mg

    $645

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    SB939 is a pan-inhibitor of histone deacetylases (HDACs; Kis = 16-247 nM for HDAC1-11).1 It inhibits proliferation of A2780, COLO 205, HCT116, and PC3 cancer cells (IC50s = 0.48, 0.56, 0.48, and 0.34 µM, respectively). SB939 (50 and 100 mg/kg) reduces tumor growth and increases survival in an HCT116 mouse xenograft model. It synergizes with pacritinib (Item No. 16709) to decrease the number of metastases in a MOLM-13 mouse xenograft model when administered at a dose of 75 mg/kg.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Wang, H., Yu, N., Chen, D., et al. Discovery of (2E)-3-{2-butyl-1-[2-diethylamino)ethyl]-1H-benzamidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J. Med. Chem. 54(13), 4694-4720 (2011).

    2. Novotny-Diermayr, V., Hart, S., Goh, K.C., et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2(5), 1-10 (2012).